Figure S8 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Q: What type of study is this?

This is a Experimental Study study.

Nikola Knoll; Sarah Masser; Blanka Bordas; Richard Y. Ebright; Guangyan Li; Devishi Kesar; Eliana Destefanis; Nicholas Kania; Diego J. Rodriguez; Jayu Jen; Sydney E. Zagar; Caleb Mensah; Zixin Chen; Samuel J. Moffitt; Erhumuoghene M. Enakireru; Yao He; Baomou Feng; Mira K. Chokshi; Cyrus Y. Jin; Srivatsan Raghavan; William R. Sellers; Kathleen M. Mulvaney

doi:10.1158/0008-5472.30125724

Key Points

Synergy was identified between the MEK1/2 inhibitor trametinib and PRMT5 inhibitor MRTX1719 in MTAP-deleted cancers.
The combination treatment shows potential to enhance effectiveness compared to single-agent therapies.
Assessment was conducted through CRISPR-based drug combinatorial screening to optimize cancer therapies.
These findings point to the need for further studies in clinical settings to validate treatment efficacy.

Implication

Observational analysis demonstrates synergy between MEK1/2 inhibitor trametinib and PRMT5 inhibitor MRTX1719, suggesting new treatment avenues for MTAP-deleted cancer.

Abstract

Figure S8. MEK1/2 inhibitor trametinib shows synergy with PRMT5 inhibitor MRTX1719.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knoll et al. (2025) studied this question.

synapsesocial.com/papers/68d4508931b076d99fa588d9 https://doi.org/10.1158/0008-5472.30125724

View at Publisher

Ask AI

Bookmark

Share

Figure S8 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S8 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading